Surprising result for the treatment of moderate to severe AD with lebrikizumab
During this MEDtalk, Andrew Blauvelt discusses the recently published 52-week data on the effectiveness and safety of lebrikizumab in treating moderate to severe atopic dermatitis (AD). The study reveals unexpectedly positive results, showing sustained improvements in all measured outcomes.